Asahi Kasei Pharma announces that it has selected MAIA Pharmaceuticals, Inc. as its U.S. partner under a strategic collaboration for the development and commercialization in the U.S. of Teribone™ osteoporosis drug (generic name: teriparatide acetate; product name in Japan: “Teribone™ 56.5 µg subcutaneous injection” and “Teribone™ 28.2 µg subcutaneous injection autoinjector”). Under the collaboration framework, MAIA will leverage

Tempus AI, Inc. a technology company leading the adoption of AI to advance precision medicine, today announced the launch of its new HRD-RNA algorithm. This next-generation model represents a significant improvement in identifying Homologous Recombination Deficiency (HRD), providing a more robust, functional assessment of tumor biology compared to traditional static DNA-based assays. Tempus HRD-RNA is an AI-driven, 1,660-gene logistic regression model designed to identify patients l

Sensei Biotherapeutics, Inc. today announced that it has acquired Faeth Therapeutics Inc. (“Faeth”), a clinical-stage biotechnology company developing multi-node therapies that target tumor metabolism and signaling. The acquisition brings Faeth’s lead asset PIKTOR, a proprietary investigational all-oral combination of serabelisib and sapanisertib that inhibits multiple nodes of the PI3K/AKT/mTOR pathway through PI3K-alpha and dual mTORC1/2 targeting, into Sensei’s pipe

Pharmacelera, a deep tech company applying Quantum Mechanics and Artificial Intelligence to revolutionize drug discovery, has closed a €6 million investment round to accelerate its expansion in the United States and grow the capabilities of its proprietary platform. Utilizing its proprietary Quantum Mechanics and Artificial Intelligence ("QaiM") algorithms, Pharmacelera is revolutionizing drug discovery by finding novel and diverse molecular candidates across the vast

Twist Bioscience Corporation, a mid-cap growth and value biotech company, today announced that it has entered into a licensing agreement with Invenra Inc. (“Invenra”), a company that has developed platform technologies to discover therapeutic antibody candidates. Under the terms of the agreement, Twist will become the co-exclusive provider, together with Invenra, of Invenra’s B-Body® bispecific antibody platform (“B-Body platform”), extending Twist’s an

Novartis today announced final results from the Phase III ALIGN study supporting a slowing decline in kidney function in adults with IgA nephropathy (IgAN) who were treated with Vanrafia® (atrasentan). Vanrafia showed a difference of 2.39 ml/min/1.73m2 in estimated glomerular filtration rate (eGFR) change from baseline vs. placebo (2-sided p = 0.057) at Week 136, 4 weeks after the end of study treatment1. Clinically meaningful results were observed with Vanrafia compared to plac

Niowave Inc., a U.S.-based global leader in medical radioisotope production, today announced a new long-term supply agreement with Novartis to deliver Actinium-225 (Ac-225). The agreement provides Novartis with a scalable supply of this critical isotope to support its growing portfolio of radioligand therapies (RLT). RLTs use a targeting component with a radioisotope to selectively target and destroy cancer cells. Financial terms of the agreement are not being disclosed. The long-te

Precision BioSciences, Inc. a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that the Company received a Study May Proceed notification from the U.S. Food and Drug Administration (FDA). This allows Precision BioSciences to initiate IRB activities and clinical trial site activation for the FUNCTION-DMD Phase 1/2 clinical trial for PBGENE-DMD for the treatment of ambu

GCCL Co., Ltd. (GCCL), a data-driven clinical trial services provider, and Medicover Integrated Clinical Services (MICS), part of Medicover, an international healthcare and diagnostic services company, have signed a Memorandum of Understanding (MOU) to collaborate on multinational clinical trial services. Through this MOU, the two companies aim to establish a collaborative framework covering Europe, the United States, and the Asia-Pacific (APAC) region. By leveraging their respectiv

Insilico Medicine a clinical-stage biotechnology company driven by generative artificial intelligence (AI), China Medical System Holdings Limited (“CMS”, 867.HK/8A8.SG), an open-platform innovative company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, today announced a series of AI‑empowered drug discovery collaborations across multiple projects in the fields of central nervous system and autoimmune diseases.